{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:26:12Z","timestamp":1787390772269,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,14]],"date-time":"2027-07-14T00:00:00Z","timestamp":1815523200000},"content-version":"am","delay-in-days":316,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["T32AG000243"],"award-info":[{"award-number":["T32AG000243"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clon.2026.104221","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:24:55Z","timestamp":1781994295000},"page":"104221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020\u20132024)"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-024X","authenticated-orcid":false,"given":"S.","family":"Kalantri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-2146","authenticated-orcid":false,"given":"J.Q.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8594-9658","authenticated-orcid":false,"given":"T.O.","family":"Akhiwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-8868","authenticated-orcid":false,"given":"R.","family":"Redman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104221_bib1","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","article-title":"Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review","volume":"7","author":"Chakraborty","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clon.2026.104221_bib2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11136-012-0344-y","article-title":"ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research","volume":"22","author":"Reeve","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clon.2026.104221_bib3","series-title":"Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products","year":"2005"},{"key":"10.1016\/j.clon.2026.104221_bib4","series-title":"Silver spring, MD: U.S. Department of health and human services, food and drug administration, oncology center of excellence; center for drug evaluation and research","article-title":"Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry","author":"UsfaD","year":"2024"},{"key":"10.1016\/j.clon.2026.104221_bib5","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"Jama"},{"key":"10.1016\/j.clon.2026.104221_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension","volume":"319","author":"Calvert","year":"2018","journal-title":"Jama"},{"key":"10.1016\/j.clon.2026.104221_bib8","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/annonc\/mdy449","article-title":"Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016","volume":"29","author":"Marandino","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib9","article-title":"Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study","volume":"2","author":"Marandino","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103649","article-title":"Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review","volume":"172","author":"Servetto","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clon.2026.104221_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100566","article-title":"Patient-Centered Perspectives: Examining Quality-of-Life Integration in Recent Phase III Lung Cancer Trials (2019-2023)","author":"Kalantri","year":"2025","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.clon.2026.104221_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100653","article-title":"Overlooked and underreported: A systematic review of quality of life in recent Phase III metastatic breast cancer trials","volume":"46","author":"Kalantri","year":"2025","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.clon.2026.104221_bib13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","article-title":"Chemotherapy Use, Performance Status, and Quality of Life at the End of Life","volume":"1","author":"Prigerson","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2026.104221_bib15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clon.2026.104221_bib16","series-title":"Applied logistic regression","author":"Hosmer","year":"2013"},{"key":"10.1016\/j.clon.2026.104221_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmjspcare-2020-002538","article-title":"Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades","volume":"12","author":"Kouzy","year":"2022","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.clon.2026.104221_bib19","series-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the national cancer institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","first-page":"67","author":"Kluetz","year":"2016"},{"key":"10.1016\/j.clon.2026.104221_bib20","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fmed.2022.968272","article-title":"A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020","volume":"9","author":"Teixeira","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.clon.2026.104221_bib21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.26502\/aimr.0123","article-title":"A 15 Year Review (2006-2020) of Patient-Reported Outcome (PRO) in United States Oncology Product Labeling and Trends in Sponsor Size and Oncology Experience","volume":"5","author":"Cooper","year":"2022","journal-title":"Arch Intern Med Res"},{"key":"10.1016\/j.clon.2026.104221_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40258-023-00827-3","article-title":"The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022","volume":"21","author":"Meregaglia","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.clon.2026.104221_bib23","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fdgth.2025.1560533","article-title":"Electronic patient-reported outcome systems and capabilities in cancer care: a systematic review","volume":"7","author":"Salmani","year":"2025","journal-title":"Front Digital Health"},{"key":"10.1016\/j.clon.2026.104221_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.clon.2026.104221_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s41687-020-00219-4","article-title":"The impact of patient-reported outcome data from clinical trials: perspectives from international stakeholders","volume":"4","author":"Cruz Rivera","year":"2020","journal-title":"J Patient-Reported Outcome"},{"key":"10.1016\/j.clon.2026.104221_bib26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.11109","article-title":"Health-related quality of life (QoL) in randomized phase III trials in oncology: Association between results of QoL, results of primary endpoint and drug approval","volume":"42","author":"Paratore","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib28","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamaoncol.2025.1002","article-title":"Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis","volume":"11","author":"Sherry","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-7-102","article-title":"Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008","volume":"7","author":"Montazeri","year":"2009","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.clon.2026.104221_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.clon.2026.104221_bib31","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jnci\/djz038","article-title":"Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials","volume":"111","author":"Kyte","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clon.2026.104221_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0959-8049(96)00412-1","article-title":"Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office","volume":"33","author":"Fayers","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2026.104221_bib33","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s11136-018-1860-1","article-title":"Quality of life of patients with gastrointestinal cancers undergoing chemotherapy","volume":"27","author":"Tantoy","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clon.2026.104221_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40268-024-00478-2","article-title":"The Importance of Patient Reported Outcomes in Oncology Clinical Trials and Clinical Practice to Inform Regulatory and Healthcare Decision-Making","volume":"24","author":"Bellino","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.clon.2026.104221_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf020","article-title":"Select updates from ASCO and ESMO 2024 for gastrointestinal cancer care","volume":"30","author":"Jang","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2026.104221_bib36","first-page":"351","article-title":"Measuring patient-reported outcomes in advanced gastric cancer","volume":"7","author":"Xu","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.clon.2026.104221_bib37","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s11136-023-03396-z","article-title":"International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials","volume":"32","author":"Brady","year":"2023","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clon.2026.104221_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/CCO.0b013e32816f7704","article-title":"Health-related quality-of-life assessment in gastrointestinal cancer: are results relevant for clinical practice?","volume":"19","author":"Conroy","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib39","first-page":"433","article-title":"Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial","volume":"5","author":"Anwar","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.clon.2026.104221_bib40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/cncr.33315","article-title":"Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer","volume":"127","author":"van Seventer","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2026.104221_bib41","first-page":"2025","article-title":"Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer","volume":"16","author":"Shen","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clon.2026.104221_bib42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12885-019-5579-3","article-title":"Health-related quality of life as an endpoint in oncology phase I trials: a systematic review","volume":"19","author":"Fiteni","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2026.104221_bib43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2229-3485.86879","article-title":"Patient-reported outcomes: A new era in clinical research","volume":"2","author":"Deshpande","year":"2011","journal-title":"Perspect Clin Res"},{"key":"10.1016\/j.clon.2026.104221_bib44","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1078-0432.CCR-24-4073","article-title":"Revolutionizing Patient-Reported Outcomes Analysis for Oncology Drug Development Using Population Models","volume":"31","author":"Zhou","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2026.104221_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102833","article-title":"Outcomes that matter to patients with cancer: living longer and living better","volume":"76","author":"Tregear","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.clon.2026.104221_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jncimonographs\/lgae043","article-title":"Global perspectives on patient-centered outcomes: advancing patient-centered cancer clinical trials globally","volume":"2025","author":"Monge","year":"2025","journal-title":"JNCI Monogr"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:55:17Z","timestamp":1787388917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526001925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":45,"alternative-id":["S0936655526001925"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104221","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Life Endpoints in Advanced Gastrointestinal Cancer Trials: Systematic Review of Inclusion, Challenges, and Implications (2020\u20132024)","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104221"}}